Trial · NCT07892443
Type 2 Inflammation in Adults With Cystic Fibrosis
NCT07892443, Not yet recruiting, University of Virginia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Type 2 Inflammation in Adults With Cystic Fibrosis. Trials, record NCT07892443. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07892443
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Type 2 Inflammation in Adults With Cystic Fibrosis
- NCT number
- NCT07892443
- Status
- Not yet recruiting
- Enrollment
- 100 participants, estimated
- Lead sponsor
- University of Virginia
- Conditions
- Cystic Fibrosis (CF), Type 2 Inflammatory Disorders
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Baseline Stable-State Absolute Peripheral Blood Eosinophil Count | Baseline | Absolute peripheral blood eosinophil count measured during clinical stability at baseline. Eosinophil counts will be compared between participants who, after 36 months of prospective observation, are classified as having modulator-refractory CF (average of ≥2 qualifying pulmonary exacerbations per year) or modulator-responsive CF (average of \<2 qualifying pulmonary exacerbations per year). |
| Secondary | Change in Nasal Epithelial Gene Expression from Baseline to Pulmonary Exacerbation | Baseline and qualifying pulmonary exacerbations occurring up to Month 36. | Within-participant changes in nasal epithelial gene expression from stable-state baseline to qualifying pulmonary exacerbations will be evaluated using RNA sequencing. Exploratory analyses will characterize changes in gene-expression patterns associated with type 2 inflammation and recurrent pulmonary exacerbations in adults with cystic fibrosis. |
| Secondary | Change in Exhaled Breath Condensate Inflammatory Mediator Concentrations from Baseline to Pulmonary Exacerbation | Baseline and qualifying pulmonary exacerbations occurring up to Month 36. | Within-participant changes in inflammatory mediator concentrations in exhaled breath condensate will be evaluated between stable-state baseline and qualifying pulmonary exacerbations. These analyses will explore noninvasive biomarkers of airway inflammation and their association with changes in clinical state. |
| Secondary | Change in Peripheral Blood Immune Cell Phenotypes from Baseline to Pulmonary Exacerbation | Baseline and qualifying pulmonary exacerbations occurring up to Month 36. | Within-participant changes in peripheral blood immune-cell populations from stable-state baseline to qualifying pulmonary exacerbations will be characterized using high-dimensional flow cytometry. Analyses will emphasize changes in the frequency of CRTH2-positive CD4-positive Th2 effector cells, with exploratory characterization of additional immune-cell populations associated with type 2 inflammation. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39543951 | BACKGROUND |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23HL183757 | Importance of type 2 inflammation in cystic fibrosis patients with recurrent pulmonary exacerbations | Somerville, Lindsay A. L. | UNIVERSITY OF VIRGINIA | NATIONAL HEART LUNG AND BLOOD INSTITUTE | 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07892443
GET https://conductscience.org/api/trials/v1/NCT07892443/registered